Literature DB >> 25176526

The immune tolerant phase of chronic HBV infection: new perspectives on an old concept.

Antonio Bertoletti1, Patrick T Kennedy2.   

Abstract

Chronic hepatitis B virus (HBV) infection progresses through distinct disease phases that are strongly associated with patient age. The so-called immune tolerant (IT) phase represents the classical early phase of infection; it is associated with high levels of HBV replication and lack of clinical signs of liver Inflammation. Whether this phase of HBV infection is also associated with immunological features of "tolerance' has recently been challenged. Here, we review the data that dispute this concept of immune tolerance and then propose an alternative interpretation of the immunopathological events that take place during this early phase of CHB infection.

Entities:  

Mesh:

Year:  2014        PMID: 25176526      PMCID: PMC4654319          DOI: 10.1038/cmi.2014.79

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  52 in total

1.  Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B.

Authors:  Zheng Zhang; Dawei Chen; Jinxia Yao; Hui Zhang; Lei Jin; Ming Shi; Hongfei Zhang; Fu-Sheng Wang
Journal:  Clin Immunol       Date:  2006-10-18       Impact factor: 3.969

2.  Pathology of chronic hepatitis B virus infection in children: with special reference to the intrahepatic expression of hepatitis B virus antigens.

Authors:  H C Hsu; Y H Lin; M H Chang; I J Su; D S Chen
Journal:  Hepatology       Date:  1988 Mar-Apr       Impact factor: 17.425

Review 3.  Aging of the innate immune system.

Authors:  Albert C Shaw; Samit Joshi; Hannah Greenwood; Alexander Panda; Janet M Lord
Journal:  Curr Opin Immunol       Date:  2010-08       Impact factor: 7.486

4.  Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases.

Authors:  Hurng-Yi Wang; Ming-Hung Chien; Hsiang-Po Huang; Hsiao-Chi Chang; Chung-Che Wu; Pei-Jer Chen; Mei-Hwei Chang; Ding-Shinn Chen
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

5.  HIV-1-specific cytotoxic T lymphocyte responses in the first year of life.

Authors:  K Luzuriaga; D Holmes; A Hereema; J Wong; D L Panicali; J L Sullivan
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

6.  CD4 T cells with effector memory phenotype and function develop in the sterile environment of the fetus.

Authors:  Xiaoming Zhang; Brian Mozeleski; Sebastien Lemoine; Edith Dériaud; Annick Lim; Dania Zhivaki; Elie Azria; Camille Le Ray; Gwenaelle Roguet; Odile Launay; Anne Vanet; Claude Leclerc; Richard Lo-Man
Journal:  Sci Transl Med       Date:  2014-05-28       Impact factor: 17.956

7.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

8.  Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.

Authors:  Claire Dunn; Maurizia Brunetto; Gary Reynolds; Theodoros Christophides; Patrick T Kennedy; Pietro Lampertico; Abhishek Das; A Ross Lopes; Persephone Borrow; Kevin Williams; Elizabeth Humphreys; Simon Afford; David H Adams; Antonio Bertoletti; Mala K Maini
Journal:  J Exp Med       Date:  2007-03-12       Impact factor: 14.307

9.  Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.

Authors:  K Ando; T Moriyama; L G Guidotti; S Wirth; R D Schreiber; H J Schlicht; S N Huang; F V Chisari
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

10.  Mature CD8(+) T lymphocyte response to viral infection during fetal life.

Authors:  Arnaud Marchant; Victor Appay; Marianne Van Der Sande; Nicolas Dulphy; Corinne Liesnard; Michael Kidd; Steve Kaye; Olubukola Ojuola; Geraldine M A Gillespie; Ana L Vargas Cuero; Vincenzo Cerundolo; Margaret Callan; Keith P W J McAdam; Sarah L Rowland-Jones; Catherine Donner; Andrew J McMichael; Hilton Whittle
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

View more
  58 in total

Review 1.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

2.  Overview of the special issue on HBV immunity.

Authors:  Antonio Bertoletti; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2015-04-13       Impact factor: 11.530

Review 3.  Molecular biology of hepatitis B virus infection.

Authors:  Christoph Seeger; William S Mason
Journal:  Virology       Date:  2015-03-07       Impact factor: 3.616

4.  Activation of the TLR signaling pathway in CD8+ T cells counteracts liver endothelial cell-induced T cell tolerance.

Authors:  Ejuan Zhang; Hu Yan; Qian Li; Ulf Dittmer; Huimin Yan; Mengji Lu
Journal:  Cell Mol Immunol       Date:  2019-06-26       Impact factor: 11.530

Review 5.  Cellular and molecular regulation of innate inflammatory responses.

Authors:  Juan Liu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2016-10-31       Impact factor: 11.530

6.  New insights into the evolutionary rate of hepatitis B virus at different biological scales.

Authors:  You-Yu Lin; Chieh Liu; Wei-Hung Chien; Li-Ling Wu; Yong Tao; Dafei Wu; Xuemei Lu; Chia-Hung Hsieh; Pei-Jer Chen; Hurng-Yi Wang; Jia-Horng Kao; Ding-Shinn Chen
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

7.  Comparison of antibody response to hepatitis B vaccination in infants with positive or negative maternal hepatitis B e antigen (HBeAg) in cord blood: implication for the role of HBeAg as an immunotolerogen.

Authors:  Hongyu Huang; Mingzhe Ning; Jingli Liu; Jie Chen; Jing Feng; Yimin Dai; Yali Hu; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2019-03-19       Impact factor: 3.452

8.  CMI: Highlights in last three years.

Authors:  Zhi-Qing Hu
Journal:  Cell Mol Immunol       Date:  2016-08-29       Impact factor: 11.530

Review 9.  CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated.

Authors:  Bashar M Attar
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-02-25

10.  Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in Sera of Patients at Different Phases of Infection.

Authors:  Zhi-Tao Yang; Su-Yuan Huang; Li Chen; Feng Liu; Xiao-Hui Cai; Yang-Fan Guo; Ming-Jie Wang; Yue Han; De-Min Yu; Jie-Hong Jiang; Dong-Hua Zhang; Qi-Ming Gong; Guo-Qing Zhang; Guo-Qing Zang; Zhong-Hua Lu; Li-Hua Huang; Xin-Xin Zhang
Journal:  J Clin Microbiol       Date:  2015-04-29       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.